These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33535987)

  • 1. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
    Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
    BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy.
    Chao YK; Chang CB; Chuang WY; Wen YW; Chang HK; Tseng CK; Yeh CJ; Liu YH
    Medicine (Baltimore); 2015 Aug; 94(34):e1407. PubMed ID: 26313788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
    J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.
    Kadota T; Hatogai K; Yano T; Fujita T; Kojima T; Daiko H; Fujii S
    Cancer Sci; 2018 Jun; 109(6):2046-2055. PubMed ID: 29601131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.
    Lu H; Liu JF; Rong Y; Liu XB; Wang Y
    J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience.
    Lombardi PM; Mazzola M; Achilli P; Aquilano MC; De Martini P; Curaba A; Gualtierotti M; Bertoglio CL; Magistro C; Ferrari G
    J Surg Oncol; 2021 Mar; 123(4):923-931. PubMed ID: 33497471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy.
    Guo K; Cai L; Zhang Y; Zhu JF; Rong TH; Lin P; Hao CL; Wang WP; Li Z; Zhang LJ
    Chin J Cancer; 2012 Aug; 31(8):399-408. PubMed ID: 22572013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of patients with esophageal squamous cell carcinoma who achieve major histopathological response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Chang HK; Tseng CK; Yeh CJ; Liu YH
    Eur J Surg Oncol; 2017 Jan; 43(1):234-239. PubMed ID: 27462024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
    Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
    BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
    Wong IYH; Chung JCY; Zhang RQ; Gao X; Lam KO; Kwong DLW; Chao YK; Law SYK
    Ann Surg; 2022 Nov; 276(5):784-791. PubMed ID: 35876374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.